How does trifluoperazine work (mechanism of action)?
Trifluoperazine is a typical antipsychotic. Its main mechanism is dopamine receptor blockade in the brain, especially at D2 receptors. By antagonizing D2 signaling in dopaminergic pathways, it reduces psychotic symptoms driven by excess dopamine activity.[1]
Which dopamine receptors does it block, and what does that change?
At antipsychotic-relevant sites, trifluoperazine primarily blocks D2 receptors. This lowers dopamine-mediated neurotransmission in pathways involved in hallucinations, delusions, and other psychotic phenomena.[1]
Because it is a “typical” (first-generation) antipsychotic, its strong D2 antagonism is closely linked to both its antipsychotic effect and many of its characteristic adverse effects (such as extrapyramidal symptoms). [1]
Does it have other receptor actions besides dopamine?
Trifluoperazine’s defining mechanism is D2 receptor antagonism. Sources commonly describe it as a dopamine antagonist rather than emphasizing a distinct primary action at other receptor classes.[1]
What is the practical outcome of its dopamine blockade?
By reducing D2-driven signaling, trifluoperazine can decrease core psychotic symptoms. Its D2 antagonism also explains why patients may experience dopamine-related side effects, including movement disorders.[1]
What do patients usually notice as side effects tied to the mechanism?
Common medication effects associated with D2 blockade (from typical antipsychotics) include extrapyramidal symptoms such as tremor, rigidity, or akathisia, since dopamine signaling in the nigrostriatal pathway is reduced when D2 receptors are blocked.[1]
Sources
- https://www.ncbi.nlm.nih.gov/books/NBK537218/